A bioassay of @entity32547 for possible carcinogenicity was conducted by administering the test chemical in feed to Fischer 344 @entity35 and B6C3F1 @entity19 . Groups of 35 @entity35 and 35 @entity19 of each sex were administered @entity32547 at one of the following doses, either 3,700 or 7,500 ppm for @entity35 and either 600 or 1,200 ppm for @entity19 . The @entity35 were administered the chemical for 78 weeks, then observed for 26 or 27 additional weeks; the @entity19 were administered the chemical for 80 weeks, then observed for 25-27 additional weeks. Matched controls consisted of 15 untreated @entity35 and 15 untreated @entity19 of each sex. All surviving @entity35 were killed at 104 or 105 weeks, all surviving @entity19 at 105-107 weeks. Mean body weights of the dosed @entity35 and @entity19 of each sex were consistently lower than those of corresponding control animals, and the @entity308 in mean body weight were dose related. Mortality in the groups of @entity35 and @entity19 did not, however, show dose-related trends, and sufficient numbers of animals of both dosed and control groups were at risk for the development of late-appearing @entity5 . In male @entity35 , @entity652 or @entity420 of the large intestine (colon or rectum) occurred at incidences having a significant dose-related trend (P=0.015). The direct comparison of the incidences in each of the dosed groups with that in the control group was not significant (controls 0/14, low-dose 4/34, high-dose 8/35). In the females, 3/33 low-dose and 5/32 high-dose animals, but no control animals, had this @entity5 . In addition, @entity242 were observed in the colon of one low-dose male and one high-dose female. The laboratory historical records showed no incidence of @entity652 or @entity420 of the large intestine in 260 females and only one @entity6523 in 260 males. Assuming a spontaneous incidence of 1/261 (0.038%) and a binomial distribution of such @entity5 , the occurrence seen in the male and female high-dose groups are both significantly (P<0.001) different from the expected value. Thus, these @entity5 are considered to be related to administration of the test chemical. In female @entity19 , the combined incidence of @entity8055 showed a significant dose-related trend (P=0.002), and the incidence in the high-dose group was significant (P=0.003) when compared with that in the control group (controls 2/15, low-dose 11/34, high-dose 19/32). The incidence of @entity157 , considered alone, also was significant in female @entity19 , showing a dose-related trend (P=0.010) and a P value of 0.039 for the comparison of the high-dose group with the control group. In the males, the combined incidence of @entity8055 was not significant. It is concluded that under the conditions of this bioassay, @entity32547 was carcinogenic in Fischer 344 @entity35 , inducing @entity420 of the colon in both males and females. Although @entity32547 was not carcinogenic in male B6C3F1 @entity19 , the chemical was carcinogenic in females, inducing @entity8055 .

Bioassay of XXXX for possible carcinogenicity.

@entity652 :: ('MESH:D000236', 'Disease') :: ['adenomas'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depressions'] @entity8055 :: ('MESH:D018248', 'Disease') :: ['hepatocellular adenomas and carcinomas'] @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcomas'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity6523 :: ('MESH:D018256', 'Disease') :: ['adenomatous polyp'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity157 :: ('MESH:D006528', 'Disease') :: ['hepatocellular carcinomas'] @entity32547 :: ('MESH:D010621', 'Chemical') :: ['phenazopyridine hydrochloride'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas']
@entity32547 :: (MESH:D010621,Chemical) :: ['phenazopyridine hydrochloride']
